Stock Analiz

Gossamer Bio, Inc. GOSS

Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026

$10.97Market cap $67M
Open the interactive analysis →

Gossamer Bio, Inc. (GOSS) is a healthcare company listed in the US with a market value of about $67M. In the twelve months to September 30, 2026 it had revenue of $78M and net income of -$125M, a net margin of -159.5%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is value (2/5); the weakest is shareholder returns (0/5).

Key numbers: a P/E of 0.3, a 5-year average ROIC of -249%.

About Gossamer Bio

Gossamer Bio is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2019. It was profitable in 0 of the last 9 years in our data. Its share count rose by 170% over three years (dilution for shareholders). It spends 359% of revenue on research and development.

Score: 1.0 / 5

Value2/5
Future growth1/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)0.3
Forward P/E—
P/FCF—
P/S0.9
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-232.6%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-57.7%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-200.4%
ROIC (5-yr avg.)-249.4%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$78M$48M$115M$0$0—————
Net income-$125M-$170M-$57M-$180M-$229M-$234M-$243M-$180M-$147M-$7M
Free cash flow-$156M-$171M-$3M-$159M-$187M-$190M-$178M-$148M-$55M—
EPS (diluted)$34.94$-0.75$-0.25$-1.18$-2.71$-3.13$-3.55$-3.29$-22.59$-0.74
Net margin-159.5%-351.5%-49.3%———————
ROIC——-135.8%-233.7%-519.1%-109.0%-51.2%-47.5%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Gossamer Bio’s P/E ratio?

About 0.3, based on the last twelve months of diluted earnings per share.

Does Gossamer Bio pay a dividend?

Not currently.

Is Gossamer Bio a good stock to buy?

We do not give buy or sell advice. Gossamer Bio scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.